Precious Metals ETFs See Inflow Surge Amid Broad Market Rotation
I'm LongbridgeAI, I can summarize articles.Global gold ETFs recorded significant net inflows in August 2026, driving volume spikes in physical gold trusts and leveraged derivatives. This roundup examines structural fund flows within the sector and recent clinical updates from targeted biotech players.
Global commodity and precious metals trading volumes expanded significantly in August 2026, with gold prices breaking a multi-month downtrend on the back of robust Asian demand and persistent central bank purchasing. According to people familiar with the market dynamics, global gold ETFs recorded approximately USD 3 billion in net inflows in July, reversing previous consecutive months of outflows. This macroeconomic shift is directly impacting the performance of physical gold trusts and related inverse leveraged products.
iShares Gold Trust Micro (IAUM.US)
The passively managed micro ETF, which tracks physical gold bullion, has shown unusual trading activity amid recent market rotation. Data from early August 2026 indicates that precious metals daily trading volume touched USD 7.9 billion, representing 187% of its 30-day average. The iShares Gold Trust Micro accounted for a substantial portion of this incremental volume. The fund is targeting a continued influx of hedging capital from small-scale portfolios, leveraging a lower expense ratio compared to its peers.
Direxion Daily Gold Miners Index Bear 2X Shares (DUST.US)
The leveraged instrument, designed to provide a 200% inverse exposure to the daily performance of the gold miners index, recently recorded technical movements, including a bullish 200-day moving average crossover in mid-July 2026. Furthermore, filings show that issuer Direxion executed reverse splits for several products, including this ETF, in February 2026, aiming to optimize short-term bearish hedging efficiency for intraday traders.
Cognition Therapeutics (CGTX.US)
Operating outside the commodities sector, the clinical-stage biopharmaceutical company has also garnered recent capital attention. The company's Q2 2026 financial results showed a narrowed net loss of USD 3.9 million, or USD 0.04 per share, with research and development expenses falling significantly to USD 5.1 million from USD 11.5 million a year earlier. On the pipeline front, the company is targeting a mid-2027 start for the pivotal Phase 3 registration program of zervimesine for dementia with Lewy bodies (DLB). As of June 2026, its cash reserves stood at approximately USD 34.8 million, bolstered by grant funding from the National Institute on Aging.
This article does not constitute investment advice.